| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.037 | 0.5 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |